PGLa vs PR-39 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
PGLa is a 22-residue alpha-helical antimicrobial peptide co-isolated with magainin-2 from the skin of the African clawed frog Xenopus laevis. Individually, PGLa and magainin-2 show modest antimicrobial activity, but when combined at equimolar ratios, they exhibit synergistic kill...
Calculate PGLa dose →PR-39 is a 39-residue proline- and arginine-rich antimicrobial peptide from porcine neutrophil granules. Unlike classical membrane-disrupting AMPs, PR-39 kills bacteria intracellularly by inhibiting DNA and protein synthesis....
Calculate PR-39 dose →| Parameter | PGLa | PR-39 |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Preclinical | Preclinical |
| Half-Life | Minutes (proteolytic) | Minutes (proteolytic) |
| Typical Dose | N/A | N/A |
| Frequency | N/A | N/A |
| Route | Research only | Research only |
| FDA Status | Not approved | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.